Author

H. B. Mirza

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:statistical model· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Research Focus:cell type annotation· 2 Research Focus:clustering· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

I. A. McNeish· 3 shared D. P. Ennis· 2 shared N. Iyer· 2 shared O. Le Saux· 2 shared P. Spiliopoulou· 2 shared S. Spear· 2 shared A. P. Costa-Pereira· 1 shared A. P. Siskos· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

I. A. McNeish

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The genomic trajectory of ovarian high grade serous carcinoma is determined in STIC lesions

Z. Cheng, D. P. Ennis, B. Lu, H. B. Mirza, C. Sokota, B. Kaur, N. Singh, O. Le Saux, G. Russo, G. Giannone, L. A. Tookman, J. Krell, J. McDermott, C. Barnes, I. A. McNeish

This study shows that high ploidy and whole genome duplication in ovarian high-grade serous carcinoma originate in STIC lesions, indicating early determination of the tumor's genomic trajectory.

bioRxiv · Mar 11, 2024 · PreprintCancer Biology

cMYC-mediated immune repression is reversed by inhibition of H3K9/H3K27 methylation maintenance

I. Dye, S. Laing, I. Garner, H. B. Mirza, N. Iyer, N. Brady, P. Spiliopoulou, S. Spear, J. Robinson, F. Fiorentino, M. J. Fuchter, D. J. Murphy, I. J. McNeish, R. Brown

This study shows that inhibiting H3K27/H3K9 methylation maintenance reverses cMYC-mediated immune repression in cancer, improving survival in mouse models.

bioRxiv · Oct 18, 2023 · PreprintCancer Biology

Heme oxygenase-1 expressing omental macrophages as a therapeutic target in ovarian high grade serous carcinoma

S. Spear, O. Le Saux, H. B. Mirza, K. Tyson, J. Bickel, F. Grundland Freile, A. P. Siskos, C. Balcells, J. B. Walton, C. Woodman, D. P. Ennis, N. Iyer, C. Aguirre Hernandez, Y. Xu, P. Spiliopoulou, , I. A. McNeish

This study identifies HMOX1-expressing omental macrophages as a therapeutic target and biomarker for poor prognosis ovarian high-grade serous carcinoma.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer

J. I. Hoare, H. Hockings, J. Saxena, V. L. Silva, E. Maniati, H. B. Mirza, W. Huang, G. E. Wood, F. Nicolini, T. A. Graham, I. A. McNeish, M. Lockley

This study investigates platinum resistance in high grade serous ovarian cancer by analyzing transcriptomic features and evolutionary trajectories in resistant models.

bioRxiv · Jul 23, 2020 · PreprintCancer Biology